Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;70(2):396-403.
doi: 10.1007/s12020-020-02430-1. Epub 2020 Jul 30.

First-generation somatostatin receptor ligands and pregnancy: lesson from women with acromegaly

Magaly Vialon  1 , Solange Grunenwald  1 , Céline Mouly  1 , Delphine Vezzosi  1 , Antoine Bennet  1 , Philippe Caron  2
Affiliations
Review

First-generation somatostatin receptor ligands and pregnancy: lesson from women with acromegaly

Magaly Vialon et al. Endocrine. 2020 Nov.

Abstract

Introduction: Few data are available on the risks of first-generation somatostatin receptor ligands (SRLs) during pregnancy in women treated for acromegaly. Current recommendations suggest the withdrawal of treatment at diagnosis of pregnancy. The aims of this literature review were to evaluate the teratogenic effects and the potential impact of SRLs on maternal and fetal outcomes by comparing acromegalic patients treated or not during pregnancy.

Patients and methods: This study concerns 141 pregnancies in 127 women with acromegaly: 67 pregnancies in 62 women treated with SRLs during pregnancy and 74 pregnancies in 65 women not medically treated during pregnancy. A second analysis was then realized comparing women treated during 1st trimester only (36 pregnancies) and women treated longer (20 pregnancies).

Results: One malformation (ureteral stenosis) was reported in a newborn of a woman treated with SRL during pregnancy. No difference was found concerning maternal outcomes (gestational diabetes, hypertension, headaches, and delivery mode) and fetal outcomes (birth term, height, and weight). These results were also confirmed for the second analysis.

Conclusions: This review of the literature did report one malformation without being able to prove a specific link with the first-generation SRL treatment. No significant impact on maternal and fetal outcomes is related to first-generation SRL treatment in women with acromegaly. The number of pregnancies is still low and more data are necessary to conclude on the total safety of this treatment during gestation. In the meantime, based on the nonthreatening data from this review of literature, SRL treatment can be continued and/or reintroduced during pregnancy if necessary (mainly for persistent headaches) in women with acromegaly.

Keywords: Acromegaly; Fetal malformation; Gestational diabetes; Maternal outcomes; Pregnancy; Somatostatin receptors ligands.

PubMed Disclaimer

References

    1. R. Fahlbusch, J. Honegger, M. Buchfelder, Surgical management of acromegaly. Endocrinol. Metab. Clin. N. Am. 21, 669–692 (1992)
    1. B. Swearingen, F.G. Barker, L. Katznelson, B.M. Biller, S. Grinspoon, A. Klibanski et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 83, 3419–3426 (1998) - PubMed
    1. N.R. Biermasz, H. van Dulken, F. Roelfsema, Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J. Clin. Endocrinol. Metab. 85, 4596–4602 (2000) - PubMed
    1. P. Nomikos, M. Buchfelder, R. Fahlbusch, The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur. J. Endocrinol. 152, 379–387 (2005) - PubMed
    1. P. Caron, Pathologie hypophysaire et grossesse. Méd. Clin. Endocrinol. Diabète 45, 1–6 (2010).

LinkOut - more resources